CCDC85A

Across TCGA pan-cancer cohorts, CCDC85A mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CCDC85A data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CCDC85A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCDC85A expression acts as an unfavorable survival marker.

PDAC, LUAD, and LSCC are the cancer types where CCDC85A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.493	0.835	.002	39	view →
LUAD	DFS	Quartile	All	0.818	1.000	.003	12	view →
LSCC	DFS	Median	All	0.884	0.980	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CCDC85A–PDAC (DFS)

Open the PDAC breakdown →